Alkermes (ALKS) Assets Average (2011 - 2026)
Alkermes' (ALKS) quarterly Assets Average came in at $3.4 billion in Q1 2026, up 63.02% year-on-year from $2.1 billion in Q1 2025, and up 40.04% on a QoQ basis from $2.4 billion in Q4 2025.
Alkermes (ALKS) Assets Average (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Assets Average data on file, last reported at $3.4 billion in Q1 2026.
- On a quarterly basis, Assets Average rose 63.02% year-over-year to $3.4 billion in Q1 2026; TTM through Mar 2026 was $3.4 billion, a 63.02% increase from a year earlier, with the FY2025 full-year figure at $2.3 billion, up 8.37% from the prior year.
- Assets Average for Q1 2026 stood at $3.4 billion, up from $2.4 billion in the prior quarter.
- Over the last five years, Assets Average for ALKS reached as high as $3.4 billion in Q1 2026 and fell as low as $1.9 billion in Q1 2023.
- Historically, Assets Average has averaged $2.2 billion across 5 years, with a median of $2.1 billion in 2024.
- Across the five-year window, Assets Average retreated 4.63% in 2024 and soared 63.02% in 2026, its largest moves.
- Year by year, Assets Average stood at $2.0 billion in 2022, then increased by 13.05% to $2.2 billion in 2023, then slipped by 4.63% to $2.1 billion in 2024, then climbed by 14.38% to $2.4 billion in 2025, then jumped by 40.04% to $3.4 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $3.4 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.30 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 68.63 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 3.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.37 Bn |
| Dec 31, 2025 | 2.41 Bn |
| Sep 30, 2025 | 2.29 Bn |
| Jun 30, 2025 | 2.17 Bn |
| Mar 31, 2025 | 2.07 Bn |
| Dec 31, 2024 | 2.11 Bn |
| Sep 30, 2024 | 2.18 Bn |
| Jun 30, 2024 | 2.17 Bn |
| Mar 31, 2024 | 2.13 Bn |
| Dec 31, 2023 | 2.21 Bn |
| Sep 30, 2023 | 2.23 Bn |
| Jun 30, 2023 | 2.05 Bn |
| Mar 31, 2023 | 1.94 Bn |
| Dec 31, 2022 | 1.95 Bn |
| Sep 30, 2022 | 1.95 Bn |
| Jun 30, 2022 | 1.97 Bn |
| Mar 31, 2022 | 2.00 Bn |
| Dec 31, 2021 | 2.01 Bn |
| Sep 30, 2021 | 1.97 Bn |
| Jun 30, 2021 | 1.91 Bn |